Abrocitinib Process and Pharmaceutical Composition Patents
The development and marketing of abrocitinib involve distinct patent protections for both its manufacturing process and its final pharmaceutical composition. These patents are crucial for maintaining market exclusivity and recouping research and development investments.
How are Abrocitinib's Manufacturing Processes Patented?
Patents for the synthesis of abrocitinib cover specific chemical reactions, intermediates, and purification methods employed in its large-scale production. These process patents aim to protect the most efficient and cost-effective ways to manufacture the drug substance. For instance, a patent might detail a novel catalytic step, a specific solvent system, or a unique crystallization technique that results in higher purity or yield.
What Does a Pharmaceutical Composition Patent for Abrocitinib Cover?
A pharmaceutical composition patent for abrocitinib protects the final drug product as formulated for patient use. This includes not only the active pharmaceutical ingredient (API) but also any excipients, such as binders, fillers, disintegrants, and coatings, and how they are combined to create the dosage form, like tablets or capsules. These patents ensure that the specific formulation's stability, bioavailability, and patient compliance are also protected.
When Do Patents for Abrocitinib Typically Expire?
The expiry dates for abrocitinib's patents depend on their filing and grant dates, as well as any applicable patent term extensions or adjustments. Patent protection in the pharmaceutical industry generally lasts for 20 years from the filing date, but various extensions can be granted. Information on specific patent expiry dates for abrocitinib can be found on resources like DrugPatentWatch.com [1].
Can Generic Versions of Abrocitinib Enter the Market Before Patent Expiry?
The entry of generic versions of abrocitinib is generally restricted until the expiration of relevant patents. However, patent challenges, such as Paragraph IV certifications in the United States, can lead to earlier generic entry if a competitor successfully argues that the patented claims are invalid or not infringed. The landscape of patent litigation and potential challenges is dynamic and influences market entry timelines for generics.
What are the Key Differences Between Process and Composition Patents for Drugs?
Process patents protect the method of making a drug, while composition patents protect the drug itself and its formulation. A competitor might develop a different synthesis route to produce the same abrocitinib molecule, thus not infringing a process patent, but they would still infringe a composition patent if they sold the drug in the same patented formulation. Conversely, if a competitor developed a new formulation of abrocitinib, it might be patentable as a new composition, even if the manufacturing process is similar to an existing one.
Who Manufactures Abrocitinib?
Abrocitinib is developed and manufactured by Pfizer Inc. [2].
---
Sources:
1. DrugPatentWatch.com
2. Pfizer Inc.